The Supervisory Board of BRASTER S.A., Polish innovative company using liquid crystal contact thermography technology for breast oncology, held its meeting on 05/02/2014 and recommended the Management Board to take all necessary steps to transfer the trading of the Company stocks from the New Connect to the regulated market of the Warsaw Security Exchange.
"BRASTER has been dynamically pursuing its targets. The recent results of the THERMACRAC trial have confirmed that our TESTER can become a valuable complement to early breast cancer diagnosing. However, before we launch the device, we need to do a number of things and this is why we will look for additional financing. The switch to the main floor is a great opportunity to us and, at the same time, will highlight our credibility. I believe our Investors will appreciate the potential of our Company and the potential of the TESTER on global markets.” - said Krzysztof Pawelczyk, BRASTER S.A.’s President.